Press release
Lipodystrophy Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Boehringer Ingelheim, Gilead Sciences, Aegerion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Amryt Pharma, Akcea Therapeutics
To Know in detail about the Lipodystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lipodystrophy Market Forecast
Some of the key facts of the Lipodystrophy Market Report: https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• The Lipodystrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to DelveInsight's projections, there were 3,000 incident cases of lipodystrophy overall in the 7MM in 2021, and that number is expected to rise in 2032
• In the 7MM in 2021, the United States accounted for around 35% of all instances of lipodystrophy. In the US, there were 1,050 occurrences of lipodystrophy in 2021
• In 2021, the EU4 and the UK accounted for about 62% of all Lipodystrophy cases in the 7MM. In 2021, there were 1,850 instances of lipodystrophy in the EU4 and the UK; by 2032, more cases are expected
• In the 7MM, there were 2,300 cases of female Lipodystrophy and 700 cases of male Lipodystrophy overall in 2021
• Volanesorsen, REGN4461, empagliflozin, and other new treatments for lipodystrophy are available. The market will be driven by the approval of these therapies because it will give patients new and distinctive therapeutic options.
• Key Lipodystrophy Companies: Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, Gilead Sciences, Aegerion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Amryt Pharma, Akcea Therapeutics, Theratechnologies, Glaxo Wellcome, Merck Sharp & Dohme LLC, Pfizer, Regeneron Pharmaceuticals, Rhythm Pharmaceuticals, Inc., Eli Lilly and Company, Sanofi, and others
• Key Lipodystrophy Therapies: WAYLIVRA (volanesorsen), REGN4461, MIBAVADEMAB, Empagliflozin, tenofovir DF, Metreleptin, REGN4461, metreleptin, Apidra, AKCEA-ANGPTL3-LRx, Tesamorelin, Lamivudine, Zidovudine, raltegravir, Genotropin, REGN4461, Setmelanotide, Baricitinib, and others
• The Lipodystrophy epidemiology based on gender analyzed that Females have higher prevalence of Lipodystrophy in comparison to males
• The Lipodystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lipodystrophy pipeline products will significantly revolutionize the Lipodystrophy market dynamics.
Lipodystrophy Overview
Lipodystrophy is characterized by a pathological increase of adipose tissue (lipohypertrophy) in other bodily regions as well as a total or partial loss of adipose tissue (lipoatrophy).
Get a Free sample for the Lipodystrophy Market Report
https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Lipodystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Lipodystrophy Epidemiology Segmentation:
The Lipodystrophy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Lipodystrophy
• Prevalent Cases of Lipodystrophy by severity
• Gender-specific Prevalence of Lipodystrophy
• Diagnosed Cases of Episodic and Chronic Lipodystrophy
Download the report to understand which factors are driving Lipodystrophy epidemiology trends @ Lipodystrophy Epidemiology Forecast
https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Lipodystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lipodystrophy market or expected to get launched during the study period. The analysis covers Lipodystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Lipodystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Lipodystrophy Therapies and Key Companies
• WAYLIVRA (volanesorsen): Ionis Pharmaceuticals
• REGN4461/ MIBAVADEMAB: Regeneron Pharmaceuticals
• Empagliflozin: Boehringer Ingelheim
• tenofovir DF: Gilead Sciences
• Metreleptin: Aegerion Pharmaceuticals, Inc.
• REGN4461: Regeneron Pharmaceuticals
• metreleptin: Amryt Pharma
• Apidra: Sanofi
• AKCEA-ANGPTL3-LRx: Akcea Therapeutics
• Tesamorelin: Theratechnologies
• Lamivudine/Zidovudine: Glaxo Wellcome
• raltegravir: Merck Sharp & Dohme LLC
• Genotropin: Pfizer
• REGN4461: Regeneron Pharmaceuticals
• Setmelanotide: Rhythm Pharmaceuticals, Inc.
• Baricitinib: Eli Lilly and Company
Discover more about therapies set to grab major Lipodystrophy market share @ Lipodystrophy Treatment Market
https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Lipodystrophy Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Lipodystrophy Companies: Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, Gilead Sciences, Aegerion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Amryt Pharma, Akcea Therapeutics, Theratechnologies, Glaxo Wellcome, Merck Sharp & Dohme LLC, Pfizer, Regeneron Pharmaceuticals, Rhythm Pharmaceuticals, Inc., Eli Lilly and Company, Sanofi, and others
• Key Lipodystrophy Therapies: WAYLIVRA (volanesorsen), REGN4461, MIBAVADEMAB, Empagliflozin, tenofovir DF, Metreleptin, REGN4461, metreleptin, Apidra, AKCEA-ANGPTL3-LRx, Tesamorelin, Lamivudine, Zidovudine, raltegravir, Genotropin, REGN4461, Setmelanotide, Baricitinib, and others
• Lipodystrophy Therapeutic Assessment: Lipodystrophy current marketed and Lipodystrophy emerging therapies
• Lipodystrophy Market Dynamics: Lipodystrophy market drivers and Lipodystrophy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Lipodystrophy Unmet Needs, KOL's views, Analyst's views, Lipodystrophy Market Access and Reimbursement
To know more about Lipodystrophy companies working in the treatment market, visit @ Lipodystrophy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Lipodystrophy Market Report Introduction
2. Executive Summary for Lipodystrophy
3. SWOT analysis of Lipodystrophy
4. Lipodystrophy Patient Share (%) Overview at a Glance
5. Lipodystrophy Market Overview at a Glance
6. Lipodystrophy Disease Background and Overview
7. Lipodystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Lipodystrophy
9. Lipodystrophy Current Treatment and Medical Practices
10. Lipodystrophy Unmet Needs
11. Lipodystrophy Emerging Therapies
12. Lipodystrophy Market Outlook
13. Country-Wise Lipodystrophy Market Analysis (2019-2032)
14. Lipodystrophy Market Access and Reimbursement of Therapies
15. Lipodystrophy Market Drivers
16. Lipodystrophy Market Barriers
17. Lipodystrophy Appendix
18. Lipodystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Lipodystrophy Pipeline https://www.delveinsight.com/report-store/lipodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Lipodystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lipodystrophy market. A detailed picture of the Lipodystrophy pipeline landscape is provided, which includes the disease overview and Lipodystrophy treatment guidelines.
Lipodystrophy Epidemiology https://www.delveinsight.com/report-store/lipodystrophy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Lipodystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Lipodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products
Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipodystrophy Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Boehringer Ingelheim, Gilead Sciences, Aegerion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Amryt Pharma, Akcea Therapeutics here
News-ID: 3153294 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Lipodystrophy
Lipodystrophy Market Detailed Industry Report Analysis 2025-2034
Introduction
Lipodystrophy is a rare and complex metabolic disorder characterized by the abnormal distribution or complete absence of body fat. Patients may present with severe insulin resistance, hypertriglyceridemia, fatty liver disease, and heightened cardiovascular risks, in addition to visible physical changes. The psychological and quality-of-life burden is substantial, making effective treatment critical.
Historically, management relied on symptomatic control through insulin sensitizers, lipid-lowering drugs, and lifestyle interventions. The approval of metreleptin (a recombinant…
Lipodystrophy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Lipodystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Lipodystrophy Research. Learn more about our innovative pipeline…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
HIV Associated Lipodystrophy Syndrome Market 2017-2025 | TMR Research
Global HIV Associated Lipodystrophy Syndrome Market: Snapshot
HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus (HIV)-infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Patients have lipohypertrophy, an abnormal central fat accumulation or lipoatrophy, localized loss of fat tissue, or a mixed clinical presentations representing both. The complex morphological signs associated with lipodystrophy syndrome inhibits our understanding of the etiology…
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy.
Download the sample report @ https://www.pharmaproff.com/request-sample/1077
Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy.
Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis
The…
HIV-associated Lipodystrophy Market Research Report 2017
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities,…
